Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells

被引:10
|
作者
Hu, Dong [1 ]
Yang, Ruyue [1 ]
Wang, Guidan [2 ]
Li, Hao [1 ]
Fan, Xulong [1 ]
Liang, Gaofeng [1 ]
机构
[1] Henan Univ Sci & Technol, Sch Basic Med & Forens Med, Luoyang 471023, Peoples R China
[2] Henan Univ Sci & Technol, Sch Med Technol & Engn, Luoyang 471023, Peoples R China
来源
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2024年 / 19卷
关键词
tumor; CAR-T cells; immune escape; exosome; B-ALL; EXTRACELLULAR VESICLES; DRUG-DELIVERY; STEM-CELLS; ANTIGEN; EFFICACY; CANCER; RESISTANCE; LEUKEMIA; ESCAPE;
D O I
10.2147/IJN.S445101
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Adoptive T cells immunotherapy, specifically chimeric antigen receptor T cells (CAR -T), has shown promising therapeutic efficacy in the treatment of hematologic malignancies. As extensive research on CAR -T therapies has been conducted, various challenges have emerged that significantly hampered their clinical application, including tumor recurrence, CAR -T cell exhaustion, and cytokine release syndrome (CRS). To overcome the hurdles of CAR -T therapy in clinical treatment, cell -free emerging therapies based on exosomes derived from CAR -T cells have been developed as an effective and promising alternative approach. In this review, we present CAR -T cell -based therapies for the treatment of tumors, including the features and benefits of CAR -T therapies, the limitations that exist in this field, and the measures taken to overcome them. Furthermore, we discuss the notable benefits of utilizing exosomes released from CAR -T cells in tumor treatment and anticipate potential issues in clinical trials. Lastly, drawing from previous research on exosomes from CAR -T cells and the characteristics of exosomes, we propose strategies to overcome these restrictions. Additionally, the review discusses the plight in large-scale preparation of exosome and provides potential solutions for future clinical applications.
引用
收藏
页码:2773 / 2791
页数:19
相关论文
共 50 条
  • [31] Current challenges and emerging opportunities of CAR-T cell therapies
    Abreu, Teresa R.
    Fonseca, Nuno A.
    Goncalves, Nelio
    Moreira, Joao Nuno
    JOURNAL OF CONTROLLED RELEASE, 2020, 319 : 246 - 261
  • [32] CAR-T cells in multiple myeloma: current status
    Normann Steiner
    Eberhard Gunsilius
    memo - Magazine of European Medical Oncology, 2020, 13 : 43 - 49
  • [33] Biomarkers for CAR-T Cell Therapy
    不详
    TRANSFUSIONSMEDIZIN, 2024, 14 (03) : 123 - 124
  • [34] CAR-T Cell Therapy and Beyond
    Dotti, Gianpietro
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S4 - S4
  • [35] Target selection for CAR-T therapy
    Wei, Jianshu
    Han, Xiao
    Bo, Jian
    Han, Weidong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [36] Building safety into CAR-T therapy
    Peters, Daniel T.
    Savoldo, Barbara
    Grover, Natalie S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (03)
  • [37] CAR-T Cell Therapy for Lymphoma
    Ramos, Carlos A.
    Heslop, Helen E.
    Brenner, Malcolm K.
    ANNUAL REVIEW OF MEDICINE, VOL 67, 2016, 67 : 165 - 183
  • [38] Current state of CAR-T therapy for T-cell malignancies
    Luo, Liangkui
    Zhou, Xuan
    Zhou, Lijuan
    Liang, Zhao
    Yang, Jilong
    Tu, Sanfang
    Li, Yuhua
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [39] Current state of CAR-T therapy for T-cell malignancies
    Luo, Liangkui
    Zhou, Xuan
    Zhou, Lijuan
    Liang, Zhao
    Yang, Jilong
    Tu, Sanfang
    Li, Yuhua
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [40] CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
    Zhang, Xiaomin
    Zhang, Hui
    Lan, Huixuan
    Wu, Jinming
    Xiao, Yang
    FRONTIERS IN IMMUNOLOGY, 2023, 14